Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Income tax expense | NaN | NaN | 0 | NaN |
| License and collaboration revenue | 31,738 | 114,109 | 25,634 | NaN |
| Research and development expenses-External Research And Development Expenses | 30,077 | 34,816 | 107,879 | NaN |
| Research and development expenses-Employee Related Expenses | 32,867 | 32,864 | 84,502 | NaN |
| General and administrative expenses-External General And Administrative Expenses | 13,366 | 10,054 | 18,265 | NaN |
| General and administrative expenses-Employee Related Expenses | 11,951 | 12,546 | 30,578 | NaN |
| Facility and information technology related expenses | 14,438 | 15,017 | 44,076 | NaN |
| Depreciation and amortization | 5,605 | 5,668 | 16,626 | NaN |
| Stock-based compensation | 19,044 | 20,448 | 73,796 | NaN |
| Interest and other income | 9,867 | 10,640 | 33,093 | NaN |
| Other segment items | 8,575 | -250,961 | 7,294 | NaN |
| Net loss | -94,318 | 244,297 | -112,728 | -211,561 |
| Depreciation and amortization | 5,605 | 5,668 | 5,560 | 11,066 |
| Amortization of investment discount (premiums) | 2,763 | 3,258 | 4,233 | 8,467 |
| In-process research and development charge | NaN | 0 | 14,507 | NaN |
| Amortization of debt discount | 35 | NaN | NaN | NaN |
| Stock-based compensation expense | 19,044 | 20,448 | 22,747 | 51,049 |
| Change in operating lease right-of-use assets | 2,532 | 2,518 | 2,573 | 5,297 |
| Change in fair value of derivative liabilities | 2,500 | 50 | -2,757 | 3,407 |
| Change in fair value of contingent consideration liabilities | -514 | 765 | -1,000 | 55 |
| Change in fair value of non-controlling equity investments | 16 | -3,329 | 4,937 | 2,334 |
| Realized loss (gain) on sale of marketable securities | NaN | 0 | -399 | NaN |
| Gain on sale of equity method investment | NaN | 255,146 | NaN | NaN |
| Prepaid expenses and other current assets | 31,861 | -59 | -1,625 | -2,827 |
| Accounts payable | 2,216 | 1,194 | -1,589 | 6,435 |
| Accrued expenses and other liabilities | -16,258 | 14,298 | 1,977 | -8,590 |
| Operating lease liabilities | -3,494 | -3,500 | -3,383 | -6,622 |
| Deferred revenue | -6,355 | -113,820 | -5,661 | -15,936 |
| Other long-term liabilities | 134 | -91 | -93 | -146 |
| Net cash provided by (used in) operating activities | -128,513 | -83,289 | -81,479 | -180,334 |
| Purchases of property and equipment | 2,232 | 3,734 | 5,011 | 6,201 |
| Purchases of marketable securities | 153,792 | 361,038 | 175,643 | 673,111 |
| Maturities of marketable securities | 181,293 | 218,033 | 240,644 | 383,812 |
| Proceeds from sale of marketable securities | NaN | 0 | 5,743 | NaN |
| Cash paid for acquisition, net | NaN | 0 | 78 | NaN |
| Proceeds from sale of equity method investment | NaN | 255,146 | NaN | NaN |
| Equipment financings, net | NaN | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | 25,269 | 108,407 | 65,655 | -295,500 |
| Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs | 0 | 0 | 0 | 470,513 |
| Proceeds from issuances of stock under espp | 1,510 | 0 | 1,263 | 1,501 |
| Proceeds from exercise of stock options | 2,025 | 1,886 | 412 | 2,474 |
| Proceeds from the issuance of debt, net of fees paid to lender | 93,886 | NaN | NaN | NaN |
| Proceeds from private stock issuance | NaN | 0 | NaN | NaN |
| Payments of debt issuance costs | 813 | NaN | NaN | NaN |
| Net cash provided by (used in) financing activities | 96,608 | 1,886 | 1,675 | 474,488 |
| Net change in cash, cash equivalents and restricted cash | -6,636 | 27,004 | -14,149 | -1,346 |
| Cash, cash equivalents and restricted cashbeginning of period | 301,620 | 15,495 | 290,111 | NaN |
| Cash, cash equivalents and restricted cashend of period | 294,984 | 27,004 | 274,616 | NaN |